Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Praliciguat - Cyclerion Therapeutics

Next Previous
Drug Profile

Praliciguat - Cyclerion Therapeutics

Alternative Names: IW-1973; sGC agonist-Ironwood

Latest Information Update: 11 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ironwood Pharmaceuticals
  • Developer Akebia Therapeutics; Cyclerion Therapeutics; Ironwood Pharmaceuticals
  • Class Cardiovascular therapies; Fluorobenzenes; Heart failure therapies; Isoxazoles; Pyrazoles; Pyrimidines; Small molecules
  • Mechanism of Action Soluble guanylyl cyclase agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Cardiovascular disorders; Diabetic nephropathies
  • Phase I Focal segmental glomerulosclerosis
  • Discontinued Heart failure

Most Recent Events

  • 08 Dec 2025 Akebia Therapeutics plans a phase II trial for Focal segmental glomerulosclerosis in USA (PO, tablet) in December 2025 (NCT07268638)
  • 31 Dec 2024 Phase-I clinical trials in Focal segmental glomerulosclerosis (PO)
  • 17 Dec 2024 Cyclerion and Akebia re-negotiate mutually beneficial amendment to the license agreement for praliciguat

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top